We are live on ! Find out more
AGRX

Agile Therapeutics

Delisted

AGRX was delisted on the 25th of March, 2024.

26 hedge funds and large institutions have $372K invested in Agile Therapeutics in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2626 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

38% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 8

46% less capital invested

Capital invested by funds: $683K → $372K (-$311K)

Holders
26
Holders Change
Holders Change %
0%
% of All Funds
0.42%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
6
Increased
5
Reduced
8
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
ACM
26
Aquatic Capital Management
Illinois
-$1K -74 Closed
Osaic Holdings
27
Osaic Holdings
Arizona
-$47 -4 -17%
BNP Paribas Financial Markets
28
BNP Paribas Financial Markets
France
-$13 -1 Closed
Royal Bank of Canada
29
Royal Bank of Canada
Ontario, Canada
+$12 +1 New
JP Morgan Chase
30
JP Morgan Chase
New York
+$70 +6 New

AGRX Hedge Fund Activity: Q4 2022 in Review

26 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q4 2022, worth a combined $372K — down 46% from $683K a quarter earlier.

Fund positioning in AGRX was balanced in Q4 2022: 6 funds opened new positions, 6 closed out, 5 added to existing stakes and 8 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $33.2K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $158K sold.

  • 26 institutional investors held Agile Therapeutics (AGRX) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $372K of Agile Therapeutics stock for Q4 2022, down 46% quarter-over-quarter.
  • 6 funds opened new Agile Therapeutics positions in Q4 2022 and 6 closed out, a net change of 0 holders.
  • The largest Agile Therapeutics buyer in Q4 2022 was Virtu Financial, an estimated $33.2K added.
  • The largest Agile Therapeutics seller in Q4 2022 was Perceptive Advisors, an estimated $158K sold.

Based on aggregated 13F filings for Q4 2022.